XEFO Powder and solvent for solution for injection (2013)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
XEFO 8 mg/2ml injection: powder and solvent for solution for injection.
Qualitative and quantitative composition
One vial contains 8 mg lornoxicam. After reconstitution in 2 ml solvent, reconstituted solution contains 4mg/ml of lornoxicam. For a full list of excipients, see 6.1.
Pharmaceutical form
Powder and solvent for solution for injection. Powder: Yellow solid substance. Solvent: Clear, colourless liquid, practically free from particles. The osmolarity of the reconstituted solution is about ...
Therapeutic indications
Short term treatment of moderate postoperative pain.
Posology and method of administration
This specific application form should only be used if a quick onset of pain relief is needed or if an oral application or an application via suppository is not possible. Generally the treatment should ...
Contraindications
Hypersensitivity to lornoxicam or any of the excipients. Hypersensitivity (symptoms like asthma, rhinitis, angioedema or urticaria) to other NSAIDs including acetylsalicylic acid. Thrombocytopenia. Gastro-intestinal ...
Special warnings and precautions for use
For the following disorders, XEFOlornoxicam should only be administered after careful risk-benefit assessment: Renal impairment: Lornoxicam should be administered with precaution in patients with mild ...
Interaction with other medicinal products and other forms of interaction
Concomitant administration of lornoxicam and Cimetidine: Increased plasma concentrations of lornoxicam. (No interaction between lornoxicam and ranitidine, or lornoxicam and antacids has been demonstrated). ...
Pregnancy and lactation
Pregnancy Lornoxicam is contraindicated on the third trimester of pregnancy and should not be used during pregnancy in the first and second trimesters and delivery as no clinical data on exposed pregnancies ...
Effects on ability to drive and use machines
Patients showing dizziness and/or sleepiness under treatment with lornoxicam should refrain from driving or operation machinery.
Undesirable effects
The most commonly observed adverse events of NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). ...
Overdose
At this time, there is no experience of overdose to permit definition of the consequence of an overdose, or to suggest specific managements. However, it can be expected that after an overdose with lornoxicam, ...
Pharmacodynamic properties
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non- steroidal, oxicams ATC code: M01AC05 Lornoxicam is a non-steroidal anti-inflammatory drug(NSAID) with analgesic properties ...
Pharmacokinetic properties
Absorption Lornoxicam 8 mg powder for injection is intended for intravenous (IV) as well as intramuscular (IM) administration. After IM injection, maximum plasma concentrations are achieved after approximately ...
Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Lornoxicam caused renal toxicity ...
List of excipients
Powder: Mannitol Trometamol Disodium edetate Solvent: Water for injection
Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Shelf life
Shelf life: 3 years. Single use only. Reconstituted solution can be stored up to 24 hours at +2°C to +8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, ...
Special precautions for storage
Do not store above 25°C. Keep vial in the outer carton. Protect from light. For storage conditions of the reconstituted medicinal product, see section 6.3.
Nature and contents of container
Immediate packaging 1 set contains: Powder for injection: Amber glass vial with rubber stopper, sealed with aluminium snap-off closure. Water for injection: 2 ml clear glass ampoule. Pack Sizes: 1,5, 6 ...
Special precautions for disposal and other handling
The solution for injection is prepared by dissolving the content of one vial in 2 ml water for injection from the accompanying ampoule, immediately prior to use. The appearance of the product after reconstitution ...
Marketing authorization holder
Takeda Pharma A/S Denmark, Langebjerg 1, DK-4000, Roskilde, Denmark
Date of revision of the text
April 2013.
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: